News and features
Read the latest news and features about our world-leading research, discoveries, fundraising and philanthropy. If you want to keep updated on our news, you can follow us on social media or sign up for our Search newsletter.
If you’re a journalist and want to find out more, you can contact our media relations team.
AI study 'exciting first step' towards improving post-treatment surveillance of lung cancer patients
Artificial intelligence (AI) could help guide the post-treatment surveillance of non-small cell lung cancer (NSCLC) patients and improve outcomes as a result, according to new research.
From bench to bedside and beyond: the team of scientists that transformed breast cancer treatment
A group of researchers from The Institute of Cancer Research and The Royal Marsden have won the prestigious AACR Team Science Award for breast cancer research. Hear from the winning team about their pioneering work and its impact.
AACR 2022: New 'killer' immunotherapy shows early promise in range of solid tumours
A new type of immunotherapy making use of the immune system’s ‘natural killer cells’ could offer potential against a range of cancers that can evade current treatments, early results from a phase I trial suggest.
AACR 2022: Team of scientists and clinicians wins global award for transforming breast cancer treatment
A group of UK clinical and non-clinical scientists working together across different areas of cancer research has won the AACR Team Science Award for work that has transformed treatment for many patients with breast cancer.
AI test could predict effective cancer drug combinations in less than two days
Scientists have created a prototype test that can predict which drug combinations are likely to work for cancer patients in as little as 24 to 48 hours.
New centre targets ‘undruggable’ cancers after major donation
The centre will focus on ‘targeted protein degradation’ – one of the hottest and most promising areas in drug discovery. Scientists aim to hijack normal process of protein destruction to wipe out cancer proteins that traditional targeted drugs cannot block.
Study shows more women with invasive lobular breast cancer should qualify for tailored clinical trials
A new study led by scientists at The Institute of Cancer Research, London, has changed our understanding of invasive lobular breast cancer – and could increase the number of patients who access new treatments via lobular breast cancer specific clinical trials.
Test can personalise use of immunotherapy and chemotherapy for head and neck cancer
Matching cancer patients to treatment based on their levels of a key immune protein may allow doctors to select those who would benefit most from the combination of immunotherapy and chemotherapy, researchers report.
ICR welcomes FDA approval of ‘search and destroy’ treatment
The Institute of Cancer Research, London, strongly welcomes the news that 177Lu-PSMA-617, a potent radioactive medicine that searches for tumour cells to deliver a radioactive payload, has been approved by the US Food and Drug Administration (FDA) for treating some advanced prostate cancers.
Longer course of hormonal therapy before surgery for breast cancer has greater impact on tumour growth
Treating some women with higher risk breast cancer with a longer course of hormonal therapy before surgery led to more changes in the genetic makeup of their tumours, some of which were associated with better survival outcomes.
ICR Discovery Club showcases how we take new drugs to cancer patients
Members of the Discovery Club gathered at the Royal Society of Chemistry to hear how our scientists are moving new cancer drugs into the clinic.
'Man Van' launched to speed up early diagnosis of prostate cancer and improve healthcare access
The 'Man Van', an innovative new outreach programme, has been launched today to provide free health checks for men and boost early diagnosis of prostate and other urological cancers.
